{
  "chunk_id": "V_iii_11_None_8",
  "content": "/>\nV.iii.11.1.c\n.\nEvaluating Diabetes Mellitus\nEvaluations of diabetes mellitus are assigned under\n38 CFR 4.119, diagnostic code (DC) 7913\n.  The diagnostic criteria take into account\nthe means necessary to control diabetes, specifically\nrestricted diet\noral hypoglycemic agent\none or more daily injection of insulin, and\nregulation of activities\nfrequency of specific types of care for episodes of ketoacidosis or hypoglycemic reactions\nhospitalizations, or\nvisits to a diabetic care provider\nprogressive loss of weight and strength, and\ndiabetic complications.\nNote\n:  To treat diabetes mellitus, medical providers may prescribe non-insulin injectable medications, such as Ozempic, Victoza, Trulicity, or other generic versions.  These medications are distinctly different from injectable insulin.  Like oral hypoglycemic agents, non-insulin injectable medications help lower blood glucose levels.  For rating purposes, evaluate a prescription for a non-insulin injectable medication in the same manner as a prescription for an oral hypoglycemic agent.  Do\nnot\nconsider a non-insulin injectable medication as equivalent to treatment with insulin.\nReferences\n:  For more information on\nevaluating complications of diabetes mellitus, see\nM21-1, Part V, Subpart iii, 11.2.b\n, and\nscope of diabetes mellitus claims, see\nM21-1, Part V, Subpart iii, 11.1.f\n.",
  "title": "M21-1, Part V, Subpart iii, Chapter 11 - Endocrine Conditions",
  "citation": "Part V, Subpart iii, Chapter 11, Section None",
  "source_url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180518/M21-1-Part-V-Subpart-iii-Chapter-11-Endocrine-Conditions",
  "updated": "",
  "scraped_at": "2025-06-16T22:45:53.885996",
  "tags": [
    "m21-1"
  ]
}